Effect of follicle stimulating hormone receptor gene polymorphisms in cervical cancer risk

dc.contributor.authorZidi, Sabrina
dc.contributor.authorStayoussef, Mouna
dc.contributor.authorAlsaleh, Bano L
dc.contributor.authorGazouani, Ezzedine
dc.contributor.authorMezlini, Amel
dc.contributor.authorEbrahim, Bashayer H
dc.contributor.authorLoueslati, Besma Yacoubi
dc.contributor.authorAlmawi, Wassim Y
dc.date.accessioned2022-04-01T12:56:05Z
dc.date.accessioned2023-08-19T08:55:55Z
dc.date.available2022-04-01T12:56:05Z
dc.date.available2023-08-19T08:55:55Z
dc.date.issued2017-08
dc.description.abstractFor the first time in the word, we investigated the association between five FSHR polymorphisms with the risk of cervical cancer among Tunisians. Study subjects comprised 112 Cervical Cancer (CC) patients and 164 control women. Genotyping of FSHR rs6166, rs1007541, rs11692782, rs2055571 and rs1394205 variants was done by realtime PCR, with defined clusters. The allelic distributions of the tested FSHR SNPs were comparable between CC patients and control women. In contrast, the heterozygous genotype of rs1007541 was associated with 1.8-fold increased risk of CC. Stratification according to FIGO staging revealed that the minor allele of rs1007541 was more frequent among advanced tumor stage patients, with 11-fold increased risk of CC [P < 0.0001; OR (95 % CI) = 11.32 (7.46–17.18)]. However, no significant allelic association was revealed in the rest of analyzed FSHR SNPs. Haploview analysis showed high Linkage disequilibrium (LD) between rs2055571 and rs1394205. Haplotype analysis revealed a lack of association between cases and controls. However, analysis of CC patient subgroups demonstrated enrichment of GGTAG haplotype in early tumor stage [P = 0.025; OR (95 % CI) = 0.07 (0.01–0.70)]. The FSHR variants and haplotypes may be a genetic markers for CC susceptibility and evolution among Tunisian women.en_US
dc.identifier.citationZidi, S., Stayoussef, M., Alsaleh, B.L. et al. Effect of Follicle Stimulating Hormone Receptor Gene Polymorphisms in Cervical Cancer Risk. Pathol. Oncol. Res. 23, 565–572 (2017).en_US
dc.identifier.doihttps://doi.org/10.1007/s12253-016-0152-8
dc.identifier.urihttps://edms.wexl.in/handle/1/3097
dc.language.isoenen_US
dc.publisherSpringer Netherlandsen_US
dc.subjectGenotypesen_US
dc.subjectPolymorphismen_US
dc.subjectCervical Canceren_US
dc.subjectHaplotypesen_US
dc.titleEffect of follicle stimulating hormone receptor gene polymorphisms in cervical cancer risken_US
dc.title.alternativePathology & Oncology Researchen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:

Collections